Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (65)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ikeda, M.
Right arrow Articles by Kuriyama, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, M.
Right arrow Articles by Kuriyama, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 31:322-326 (2001)
© 2001 Foundation for Promotion of Cancer Research

Radiofrequency Ablation and Percutaneous Ethanol Injection in Patients with Small Hepatocellular Carcinoma: a Comparative Study

Masafumi Ikeda, Shuichi Okada, Hideki Ueno, Takuji Okusaka and Hitoshi Kuriyama+,§

Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan

Background: Radiofrequency ablation (RFA) is a novel thermal ablation technique to achieve coagulative necrosis of hepatocellular carcinoma. A study was conducted to compare the antitumor effect and adverse effect of RFA with those of percutaneous ethanol injection (PEI) in patients with solitary small hepatocellular carcinoma.

Methods: The study population consisted of 119 consecutive patients with solitary hepatocellular carcinoma smaller than 3 cm in diameter. Among these, 23 patients were treated with RFA and the remaining 96 patients were treated with PEI. The antitumor effects of both treatments were assessed by contrast-enhanced computed tomography 1 month after treatment.

Results: Complete tumor necrosis was achieved in 23 patients (100%) of the RFA group and 90 patients (94%) of the PEI group (p = 0.48) and local recurrence rates at 1 year were 15% in the RFA group and 14% in the PEI group (p = 0.80). RFA required an average of 1.5 sessions to achieve complete necrosis, whereas PEI required an average of 4.0 sessions. As a consequence, the hospital stay in the RFA group (median 10 days) was significantly shorter than that in the PEI group (median 17 days). There were no serious adverse effects or complications except for one case of cholangitis in the PEI group, although deterioration of serum transaminase after RFA was significantly more severe than that after PEI.

Conclusion: RFA achieved complete tumor necrosis for small hepatocellular carcinoma with fewer treatment sessions compared with PEI. There were no serious complications.

+ For reprints and all correspondence Shuichi Okada, Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 1–1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. E-mail address: sokada@ncc.go.jp

§ Abbreviations: HCC, hepatocellular carcinoma; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; US, ultrasonography; CT, computed tomography; AFP, {alpha}-fetoprotein; d, differences between worst blood chemistry data after treatment and pretreatment data; T-Bil, total bilirubin; Alb, albumin; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; CRP, C-reactive protein.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
K. E. Corey and D. S. Pratt
Review: Current status of therapy for hepatocellular carcinoma
Therapeutic Advances in Gastroenterology, January 1, 2009; 2(1): 45 - 57.
[Abstract] [PDF]

Home page
 J Ultrasound MedHome page
S.-Y. Chiou, J.-B. Liu, and L. Needleman
Current Status of Sonographically Guided Radiofrequency Ablation Techniques
J. Ultrasound Med., April 1, 2007; 26(4): 487 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
L. M. Sutherland, J. A. R. Williams, R. T. A. Padbury, D. C. Gotley, B. Stokes, and G. J. Maddern
Radiofrequency ablation of liver tumors: a systematic review.
Arch Surg, February 1, 2006; 141(2): 181 - 190.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. R. Haaga, A. A. Exner, Y. Wang, N. T. Stowe, and P. J. Tarcha
Combined Tumor Therapy by Using Radiofrequency Ablation and 5-FU-Laden Polymer Implants: Evaluation in Rats and Rabbits
Radiology, December 1, 2005; 237(3): 911 - 918.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. Lencioni, D. Cioni, L. Crocetti, C. Franchini, C. D. Pina, J. Lera, and C. Bartolozzi
Early-Stage Hepatocellular Carcinoma in Patients with Cirrhosis: Long-term Results of Percutaneous Image-guided Radiofrequency Ablation
Radiology, March 1, 2005; 234(3): 961 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
A R Gillams
Liver ablation therapy
Br. J. Radiol., September 1, 2004; 77(921): 713 - 723.
[Full Text] [PDF]

Home page
 JCOHome page
T.W.T. Leung, S. Yu, P.J. Johnson, J. Geschwind, T.J. Vogl, K. Engelmann, G.J. Gores, M. Giovannini, J. O'Grady, M. Heneghan, et al.
Phase II Study of the Efficacy and Safety of Cisplatin-Epinephrine Injectable Gel Administered to Patients With Unresectable Hepatocellular Carcinoma
J. Clin. Oncol., February 15, 2003; 21(4): 652 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Takayama and M. Makuuchi
Ablation of Hepatocellular Carcinoma
Jpn. J. Clin. Oncol., July 1, 2001; 31(7): 297 - 298.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.